Aldeyra Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Burlington MA United States (2004)

Organization Overview

First Clinical Trial
2015
NCT02402309
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aldeyra Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

adx-102 (5 trials)

methotrexate (2 trials)

reproxalap (14 trials)

Drugs in Phase 2 Trials (4)

adx-629 (7 trials)

lifitegrast (xiidra) (1 trial)

loteprednol (lotemax) (2 trials)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Hypersensitivity (Phase 2)

Ichthyosis (Phase 2)

Iridocyclitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 2)

Sjogren-Larsson Syndrome (Phase 3)

Sjogren's Syndrome (Phase 3)

Syndrome (Phase 3)

Uveitis (Phase 3)

Uveitis, Anterior (Phase 3)

Vitreoretinopathy, Proliferative (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 30
  • # of Trial APIs: 7